Wyeth Pharmaceuticals
This article was originally published in The Gray Sheet
Executive Summary
ReFacto R2 kit for recombinant antihemophilic factor VIII delivery, cleared via biologics license application supplement Sept. 10, provides the first available needleless reconstitution process for powdered factor VIII and a pre-filled diluent component for hemophilia treatment, the firm says. Eliminating two of the three needles used in Wyeth's previous ReFacto delivery kit, which was not pre-filled, the revised version incorporates a syringe made by Vetter, a vial adapter manufactured by Medimop and Braun infusion components. Priced the same as the earlier version, the next generation kit adds convenience, takes less time to use and will facilitate competition with factor VIII firm Baxter, Wyeth notes. A fourth quarter launch is anticipated...
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.